[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
E J van HeldenS G EliasS L GerritseS C van EsE BoonM C HuismanN C T van GriekenH DekkerG A M S van DongenD J VugtsR BoellaardC M L van HerpenE G E de VriesW J G OyenA H BrouwersH M W VerheulO S HoekstraCatharina Willemien Menke-van der Houven van OordtPublished in: European journal of nuclear medicine and molecular imaging (2019)
Tumor uptake on [89Zr]Zr-cetuximab PET/CT failed to predict treatment benefit in patients with RAS wild-type mCRC receiving cetuximab monotherapy. BRAF mutations, right-sidedness, and low sEGFR correlated with intrinsic resistance to cetuximab.